[Inhibitory effects of Reitakutuukitokasin'i on the antigen-antibody reaction in rats investigated by measuring the increase in blood histamine level and the histamine release from peritoneal mast cells].
The antiallergic effects of Reitakutuukitokasin'i (RKS) on the increase in blood histamine level by antigen challenge were investigated in actively sensitized rats in comparison with those of azelastine and disodium cromoglycate (DSCG). The increase in blood histamine level after a systemic anaphylactic reaction elicited by intravenously injected antigen (egg albumin) was significantly inhibited by oral and intravenous administrations of RKS and azelastine or DSCG. Namely, RKS at 50 and 100 mg/kg (p.o.) caused 17% and 28% inhibition, respectively, and azelastine at 5 and 10 mg/kg (p.o.) caused 28% and 29% inhibition, respectively. RKS at 0.1 and 0.5 mg/kg (i.v.) caused 33% and 29% inhibition, respectively, and DSCG at 10 mg/kg (i.v.) caused 53% inhibition. However, large doses of RKS (500 mg/kg, p.o., 2.5 and 10 mg/kg, i.v.) caused no significant inhibition. The histamine release from rat peritoneal mast cells (RPMC) by antigen-antibody reaction was also investigated, and proved to be inhibited significantly by RKS. Namely, RKS at 5 x 10(-4), 10(-3) and 2 x 10(-3) g/ml caused 42, 71 and 79% inhibition, respectively. These results suggest that RKS is an antiallergic drug similar to azelastine and DSCG with a common inhibitory action on the release of histamine.